OIS Podcast | Ophthalmology's leading Podcast

Active
Has guests
OIS Podcast
Categories
Investing Business Entrepreneurship Health & Fitness Science
Audience & Performance Metrics
540 - 900 listeners Neutral 4.6 rating 36 reviews 418 episodes USA
Monetization Metrics
30s Ad: $19 - $23 60s Ad: $22 - $27 CPM Category: Health & Fitness
Socials metrics & links
Podcast Links

Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.

Producers, Hosts, and Production Team

No producer information available yet. Click "Find producers" to search for the production team.

Emails, Phones, and Addresses

Contact Page Emails

Emails
  • General contact email: oi***@healthegy.com
Phone Numbers
  • Customer service phone number: (631) 565-7203
Addresses
  • Mailing address: PO Box 780 Jericho, NY 11753
Form

A contact form is available on this page. You can fill out the form at this link.

General Website Emails

No website emails found.

Externally Sourced Emails

No external emails found.

RSS Emails

No RSS emails found.

Recent Hosts, Guests & Topics

Here's a quick summary of the last 5 episodes on OIS Podcast | Ophthalmology's leading Podcast.

Hosts

Dr. Rob Rothman Dr. Jai Parekh Dr. Robert Rothman

Previous Guests

Paul Smith
Paul Smith is the President and COO of Orasis Pharmaceuticals, where he leads the commercialization of innovative ophthalmic products. With over two decades of experience in the pharmaceutical industry, he has held significant roles at major companies such as Alcon and Novartis. Smith's career trajectory includes a diverse background in tech startups and ophthalmic leadership, emphasizing the importance of cross-functional experience in driving innovation. He is known for his collaborative approach and commitment to addressing unmet needs in eye care, particularly through the development of Qlosia, a novel treatment for presbyopia.
Andrew Gitkin
Andrew Gitkin is a prominent figure in the investment banking sector, currently associated with Leerink Partners. He specializes in healthcare investments, particularly in the biotech and ophthalmology fields, providing insights and strategic advice to clients navigating the complexities of capital markets.
Cameron Taylor
Cameron Taylor is a leading investment banker at Bank of America, focusing on the healthcare sector. With extensive experience in financial advisory and capital raising, he plays a crucial role in guiding biotech companies through market challenges and opportunities.
Susan Orr, PhD
Dr. Susan Orr is a seasoned expert in the biotech industry, currently with Claris Bio. She holds a PhD and has a strong background in ophthalmology research and development, contributing to innovative solutions in the field.
Anupam Dalal, MD
Dr. Anupam Dalal is a medical doctor and investment professional at Acuta Capital. He combines his medical expertise with financial acumen to identify and invest in promising biotech ventures, particularly in ophthalmology.
Dr. Pravin Dugel
Dr. Pravin Dugel is the Chairman and CEO of Ocular Therapeutix, a company focused on developing innovative therapies for ophthalmic conditions. With a strong background in clinical practice and research, he is a recognized leader in the ophthalmology field.
Michael ORourke
Michael ORourke is the CEO of Re-Vana Therapeutics, a company focused on developing innovative drug delivery solutions for ophthalmic applications. With a background in biotechnology and a strong track record in the pharmaceutical industry, ORourke has been instrumental in advancing the company's proprietary hydrogel-based technologies aimed at providing longer-lasting treatments for retinal diseases. Under his leadership, Re-Vana has raised significant funding to support its clinical and development strategies, positioning itself as a leader in the field of sustained-release biologics.
Andrew Stewart
Andrew Stewart is a seasoned executive with over 25 years of experience in the pharmaceutical industry. He has held leadership positions at prominent companies such as Bausch + Lomb, AbbVie, and Allergan. His extensive background in global business management has significantly influenced innovation in eye care, making him a respected figure in the field.
Anthony Wallace
Anthony Wallace is a healthcare veteran with 26 years of experience in the industry. He has served in leadership roles at major pharmaceutical companies including Novartis, Merck, and GlaxoSmithKline. Currently, he leads Bausch + Lomb's U.S. Surgical business and is known for his commitment to patient-centered solutions and advancing ophthalmic care.
Daphne Haim-Langford
Daphne Haim-Langford, PhD, is the Founder and CEO of Tarsier Pharma. With a strong background in pharmaceutical innovation, she has dedicated her career to developing novel therapies for ophthalmic conditions. Under her leadership, Tarsier Pharma has focused on creating bio-inspired treatments that address significant unmet needs in the field of ophthalmology, particularly in managing uveitis.
Ashley Kline
Ashley Kline is the Chief Commercial Officer at Tarsier Pharma. She brings extensive experience in commercial strategy and market development within the pharmaceutical industry. Ashley is instrumental in guiding the launch and commercialization of Tarsier's innovative therapies, ensuring that they reach the patients who need them most.

Topics Discussed

presbyopia Qlosia FDA-approved low-dose pilocarpine Orasis Pharmaceuticals ophthalmic innovation go-to-market strategy optometry patient needs ophthalmic industry investment banking biotech macroeconomic shifts regulatory confidence capital markets market volatility early-stage biotech high-quality innovation strategic interest wet AMD GA dry AMD geographic atrophy sustained drug delivery ophthalmology intravitreal injections retinal diseases AMD biodegradable drug implants EyeLief OcuLief patient compliance clinical strategy investment strategy Series B raise retinal therapeutics pharmaceutical leadership eye care patient-centered solutions organizational culture global ophthalmology markets leadership mentorship uveitis Tarsier Pharma TRS01 bio-inspired therapy inflammation intraocular pressure steroid treatments glaucoma care commercial strategy

YouTube Channel

Channel Info

OIS: Ophthalmology Innovation Source
@OphthalmologySummit

Channel Stats

Subscribers: 3,840
Total Videos: 1,250
Total Views: 542,512
Joined: Jul 10, 2014
Location: United States

Description

The Ophthalmology Innovation Summit (OIS) was conceptualized and designed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Ventures. To make his vision for OIS a reality, Emmett partnered with legendary venture capitalists Bill Link of Versant Ventures and fellow ophthalmologist/venture capitalist Gil Kliman of InterWest Partners to Co-Champion the programs. The final addition of experienced event producer Craig Simak brought the event to life. Their combined efforts have resulted in the OIS franchise which has attracted thousands of industry leaders within the ophthalmic space since the first meeting in 2009.

The OIS programs are presented annually by Healthegy, Inc. as affiliate meetings with AAO and ASCRS.

Instagram Profile

Podcast has no Instagram profile.

Episodes

Here's the recent few episodes on OIS Podcast | Ophthalmology's leading Podcast.

0:00 36:21

Bringing Presbyopia Back to the Forefront: Paul Smith of Orasis on The Rob & Jai Show, an Edition of the OIS Podcast

Hosts
Dr. Rob Rothman Dr. Jai Parekh
Guests
Paul Smith
Keywords
presbyopia Qlosia FDA-approved low-dose pilocarpine Orasis Pharmaceuticals ophthalmic innovation go-to-market strategy optometry patient needs

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.

With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.

In this episode, you'll learn:

  • Why Qlosiâ„¢ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
  • How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
  • The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
  • Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
  • What makes presbyopia such a powerful entry point into the broader continuum of vision care.

With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.

Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!

0:00 31:58

The View from the Street: Industry Trends, Strategic Shifts & Navigating Uncertainty

Guests
Andrew Gitkin Cameron Taylor Susan Orr, PhD Anupam Dalal, MD Dr. Pravin Dugel
Keywords
ophthalmic industry investment banking biotech macroeconomic shifts regulatory confidence capital markets market volatility early-stage biotech high-quality innovation strategic interest wet AMD GA dry AMD geographic atrophy

In this edition of the OIS Podcast, a powerhouse panel of investment, banking, and biotech leaders offers unfiltered insights on the current and future state of the ophthalmic industry. Featuring Andrew Gitkin (Leerink Partners), Cameron Taylor (Bank of America), Susan Orr, PhD (Claris Bio), and Anupam Dalal, MD (Acuta Capital), and Dr. Pravin Dugel, Chairman and CEO of Ocular Therapeutix, this session explores how macroeconomic and political shifts—such as RFK Jr.'s FDA rhetoric and rising interest rates—are influencing capital markets, regulatory confidence, and biotech strategy.
 
With humor, candor, and deep expertise, the panel discusses:
 
🔹The real impact of market volatility and regulatory speculation on investment in early-stage biotech.
🔹Why high-quality innovation still commands attention, even in uncertain times.
🔹How strategic interest in ophthalmology is evolving, and why later-stage assets may be getting more attention.
🔹Why board functionality may be the most underappreciated variable in getting a deal done.
🔹Trends in wet AMD, GA, and the wide-open opportunities in dry AMD and geographic atrophy.

If you’re a startup navigating today’s market, an investor looking for the next big breakthrough, or a strategist planning your pipeline, this is one episode you can’t afford to miss.
 
Don’t miss this compelling conversation. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

0:00 13:44

Breaking Barriers in Sustained Drug Delivery: Michael O’Rourke on The Rob & Jai Show edition of the OIS Podcast

Hosts
Dr. Rob Rothman Dr. Jai Parekh
Guests
Michael ORourke
Keywords
sustained drug delivery ophthalmology intravitreal injections retinal diseases AMD biodegradable drug implants EyeLief OcuLief patient compliance clinical strategy investment strategy Series B raise retinal therapeutics

In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.

O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:

🔹How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods.
🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success.
🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant.
🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics.
🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.

With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.

Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!

0:00 24:25

Industry Titans Talk Ophthalmic Innovation: Andrew Stewart & Anthony Wallace on the Rob & Jai Show

Hosts
Dr. Rob Rothman Dr. Jai Parekh
Guests
Andrew Stewart Anthony Wallace
Keywords
ophthalmic innovation pharmaceutical leadership eye care patient-centered solutions organizational culture global ophthalmology markets leadership mentorship

In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb’s U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.

In this episode, you’ll learn:
🔹How Andrew Stewart and Anthony Wallace’s extensive pharmaceutical backgrounds influence their leadership in ophthalmology.
🔹Key trends shaping the future of pharmaceutical and surgical innovations in eye care.
🔹Insights into fostering strong organizational cultures that prioritize patient outcomes.
🔹Strategies for navigating the complexities of global ophthalmology markets.
🔹Personal reflections on leadership, mentorship, and maintaining passion for patient impact.

Don't miss this inspiring conversation with two leaders whose expertise, warmth, and dedication continue to shape the future of ophthalmology. Subscribe to the OIS podcast today and stay ahead of the curve in eye care innovation!

0:00 29:05

A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation

Hosts
Dr. Robert Rothman
Guests
Daphne Haim-Langford Ashley Kline
Keywords
uveitis Tarsier Pharma TRS01 bio-inspired therapy inflammation intraocular pressure steroid treatments ophthalmology glaucoma care commercial strategy

In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.

Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.

 

In this episode, you’ll learn:

🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.

🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.

🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.

🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.

🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.

 

🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!

Ratings

Global:
4.6 rating 36 reviews

USA

4.6 ratings 32 reviews

UK

4.7 ratings 3 reviews

Australia

5.0 ratings 1 reviews

Canada

0.0 ratings 0 reviews

Ireland

0.0 ratings 0 reviews

New Zealand

0.0 ratings 0 reviews

Singapore

0.0 ratings 0 reviews

South Africa

0.0 ratings 0 reviews